89bio, Inc.

NasdaqGM:ETNB Voorraadrapport

Marktkapitalisatie: US$968.0m

89bio Beheer

Beheer criteriumcontroles 2/4

89bio's CEO is Rohan Palekar, appointed in Jul 2018, has a tenure of 6.33 years. total yearly compensation is $5.59M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 0.27% of the company’s shares, worth $2.60M. The average tenure of the management team and the board of directors is 3.3 years and 4.3 years respectively.

Belangrijke informatie

Rohan Palekar

Algemeen directeur

US$5.6m

Totale compensatie

Percentage CEO-salaris10.9%
Dienstverband CEO6.3yrs
Eigendom CEO0.3%
Management gemiddelde ambtstermijn3.3yrs
Gemiddelde ambtstermijn bestuur4.3yrs

Recente managementupdates

Recent updates

89bio: Surviving A Competitive Space - For Now

Oct 29

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

Sep 26
Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 07

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23

89bio Still Has A Chance As NASH Race Heats Up

Oct 06

89bio completes enrollment in phase 2 trial for NASH treatment

Aug 18

89Bio rallies on Deep Track Capital disclosing 10% stake

Jul 07

89bio: Undervalued Contender In Race For First NASH Drug Approval

Jul 20

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

May 07
We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio: NASH Drug Developer With Differentiated Profile

Jan 29

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

Jan 22
We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio expects to initiate Phase 2b NASH trial in 1H21

Jan 05

Analyse CEO-vergoeding

Hoe is Rohan Palekar's beloning veranderd ten opzichte van 89bio's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$175m

Mar 31 2024n/an/a

-US$165m

Dec 31 2023US$6mUS$611k

-US$142m

Sep 30 2023n/an/a

-US$127m

Jun 30 2023n/an/a

-US$119m

Mar 31 2023n/an/a

-US$105m

Dec 31 2022US$3mUS$588k

-US$102m

Sep 30 2022n/an/a

-US$104m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$101m

Dec 31 2021US$5mUS$565k

-US$90m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$5mUS$530k

-US$49m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$60m

Mar 31 2020n/an/a

-US$64m

Dec 31 2019US$1mUS$431k

-US$57m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$30m

Dec 31 2018US$708kUS$195k

-US$18m

Compensatie versus markt: Rohan's total compensation ($USD5.59M) is above average for companies of similar size in the US market ($USD3.24M).

Compensatie versus inkomsten: Rohan's compensation has increased whilst the company is unprofitable.


CEO

Rohan Palekar (58 yo)

6.3yrs

Tenure

US$5,587,661

Compensatie

Mr. Rohan Palekar serves as the Chief Executive Officer and Director at 89bio, Inc. since July 16, 2018. He is an Independent Director at Neoleukin Therapeutics, Inc since March 02, 2022 and Neurogene Inc....


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Rohan Palekar
CEO & Director6.3yrsUS$5.59m0.27%
$ 2.6m
Quoc Le-Nguyen
Chief Technical Officer5.7yrsUS$2.51m0.15%
$ 1.4m
Harry Mansbach
Chief Medical Officer5.9yrsUS$2.54m0.088%
$ 854.6k
Ryan Martins
Chief Financial Officer5.3yrsgeen gegevens0.042%
$ 409.8k
Francis Sarena
Chief Operating Officerless than a yeargeen gegevensgeen gegevens
Shiva Natarajan
Senior Vice President of Finance & Principal Accounting Officerno datageen gegevensgeen gegevens
Annie Chang
VP of Investor Relations & Corporate Communicationsless than a yeargeen gegevensgeen gegevens
Amanda Kurihara
Vice President of People & Culture3.8yrsgeen gegevensgeen gegevens
Melissa Abel
Senior Vice President of Commercial Strategyno datageen gegevensgeen gegevens
Paul Shin
Senior Vice President of R&D Operations2.8yrsgeen gegevensgeen gegevens
Michael Baldwin
Senior VP & Head of Quality1.8yrsgeen gegevensgeen gegevens
Teresa Perney
Chief Regulatory & Quality Officerless than a yeargeen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: ETNB's management team is considered experienced (3.3 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Rohan Palekar
CEO & Director6.3yrsUS$5.59m0.27%
$ 2.6m
Kathleen LaPorte
Independent Director3yrsUS$360.17k0%
$ 0
Lota Zoth
Independent Director4.3yrsUS$363.33k0%
$ 0
Michael Hayden
Independent Director6.6yrsUS$358.33k0.23%
$ 2.3m
Martin Babler
Independent Directorless than a yeargeen gegevensgeen gegevens
Steven Altschuler Buser
Independent Chairman of the Board4.7yrsUS$385.83k0%
$ 0
Charles McWherter
Directorless than a yeargeen gegevensgeen gegevens
Edward Atkinson
Independent Director2.8yrsUS$354.60k0%
$ 0
Derek DiRocco
Independent Director6.6yrsUS$352.33k0%
$ 0

4.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: ETNB's board of directors are considered experienced (4.3 years average tenure).